Cargando…

Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer

BACKGROUND: Although C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired resistance mechanisms include a second muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jiangping, Zhou, Ping, Yu, Min, Zhang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155543/ https://www.ncbi.nlm.nih.gov/pubmed/34055614 http://dx.doi.org/10.3389/fonc.2021.645224

Ejemplares similares

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
por: Kian, Waleed, et al.
Publicado: (2023)

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement
por: Wu, Jieyu, et al.
Publicado: (2016)

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2014)

Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors
por: Wu, Chang-Wei, et al.
Publicado: (2020)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
por: Yang, Guangdie, et al.
Publicado: (2021)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer
por: Clavé, Sergi, et al.
Publicado: (2023)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

Mouse Model for ROS1-Rearranged Lung Cancer
por: Arai, Yasuhito, et al.
Publicado: (2013)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment
por: Zhang, Xugang, et al.
Publicado: (2022)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020)

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology
por: Patil, Tejas, et al.
Publicado: (2022)

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants
por: Bekeschus, Sander
Publicado: (2021)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation
por: Narayanan, Ramesh, et al.
Publicado: (2013)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
por: Lim, Sun Min, et al.
Publicado: (2017)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
por: Feng, Chunlai, et al.
Publicado: (2021)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi, Giulio, et al.
Publicado: (2017)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer
por: Pailler, E., et al.
Publicado: (2015)

Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report
por: Comandini, Danila, et al.
Publicado: (2021)

Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme
por: Lim, Sun Min, et al.
Publicado: (2015)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
por: Lee, Jongmin, et al.
Publicado: (2018)

Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
por: Zhao, Jing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3egoaqnbl4e00l3qn9car79kp0